$PFE Pfizer Inc. Company Overview
Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products. It also collaborates with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates through five operating segments: Primary Care, Specialty Care and Oncology, Established Products & Emerging Markets, Animal Health, and Consumer Healthcare. The Primary Care segment includes products in therapeutic and disease areas: Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. The Specialty Care and Oncology segment comprises the Specialty Care business unit and the Oncology business unit. The Specialty Care business unit includes products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. The Oncology business unit includes pharmaceutical products addressing oncology and oncology-related illnesses. The Established Products & Emerging Markets segment comprises the Established Products business unit and the Emerging Markets business unit. The Established Products unit includes pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. The Emerging Markets unit includes human prescription pharmaceutical products sold in emerging markets, including Asia, Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. The Animal Health & Consumer Healthcare segment comprises the Animal Health business unit and the Consumer Healthcare business unit. The Animal Health unit includes products and services to prevent and treat disease in livestock and companion animals, including vaccines, parasiticides and anti-infectives. The Consumer Healthcare segment includes non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. The company was founded by Charles Pfizer and Charles Erhart in 1849 and is headquartered in New York, NY.
PFE Last Price: 32.09
Last Updated: November 24, 2013 1:23 AM EST
PFE Stock Message Board and Forum http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Pfizer Inc. PFE Officers and Executives
Name Age Officer Since Title
Mr. Ian C. Read 59 - Chairman & Chief Executive Officer
Dr. Olivier Brandicourt 57 2007 President & General Manager-Emerging Markets
Mr. Frank A. D'Amelio 55 2007 Chief Financial Officer & EVP-Business Operations
Dr. Mikael Dolsten 54 2009 President-Worldwide Research & Development
Mr. Steve Felstead - - Vice President & Head-Clinical Research
Pfizer Inc.
235 East 42nd Street
New York, New York 10017-5755
Phone
1 2127332323
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$58.99B
Net Income
$9.49B
Employees
91,500
Annual Report Below for PFE
Pfizer Inc. PFE Recent Headlines
MarketWatch News on PFE
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Pfizer profit falls, adjusts full-year views 7:24 a.m. Oct. 29, 2013 - MarketWatch.com
Pfizer net falls, adjusts full-year earnings range 7:18 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 revenue down 2% to $12.64 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 profit falls 19% to $2.59 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 EPS falls to $0.39; adj. EPS up to $0.58 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Cat's warning sign, a Michael Kors pop and the surf pounds Portugal 6:11 a.m. Oct. 29, 2013 - blogs.marketwatch.com
Apple, LinkedIn, Pfizer, Michael Kors: hot stocks 5:30 a.m. Oct. 29, 2013 - Ben Eisen
Pfizer Feels the Heat From Novartis 4:14 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Neurotrope: Intriguing Play On Alzheimer's 3:58 p.m. Nov. 22, 2013 - Seeking Alpha
Novartis ambushes Pfizer with breast cancer treatment 3:06 p.m. Nov. 22, 2013 - Seeking Alpha
4 Biotech Stocks Making Big Moves 12:47 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Two Small-Cap Biotechs to Watch 12:00 p.m. Nov. 22, 2013 - RealMoney.com
Wall Street Breakfast: Must-Know News 6:33 a.m. Nov. 22, 2013 - Seeking Alpha
Novartis to repurchase $5B in shares over two years 4:24 a.m. Nov. 22, 2013 - Seeking Alpha
Pfizer Gets FDA Nod for Xalkori Lung Cancer Drug and 2 Other Dow Movers to Watch 1:53 p.m. Nov. 21, 2013 - Wall St. Cheat Sheet
Data on Amgen's Pipeline Candidates - Analyst Blog 11:50 a.m. Nov. 21, 2013 - Zacks.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
Athersys Narrows Loss, Shares Rise - Analyst Blog 9:00 a.m. Nov. 21, 2013 - Zacks.com
Daiichi Sankyo's Factor Xa Inhibitor Edoxaban Clears Phase III Hurdle - A Major Threat To Xarelto And Eliquis 8:35 a.m. Nov. 21, 2013 - Seeking Alpha
Roche's Kadcyla Approved in the EU - Analyst Blog 5:35 p.m. Nov. 20, 2013 - Zacks.com
Will Recent News Hurt Johnson & Johnson? 5:08 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet
Amazon.com Cloud Push Seen Creating 'Losers' In IT 4:21 p.m. Nov. 20, 2013 - Investors Business Daily
Early Warning Signs of a Dividend Cut 10:39 a.m. Nov. 20, 2013 - GuruFocus.com
Daiichi Sankyo's edoxaban holds its own in clinical testing 10:26 a.m. Nov. 20, 2013 - Seeking Alpha
EU Clears Roche Cancer Drug 5:44 a.m. Nov. 20, 2013 - WSJ.com
More Boards Recruit Ex-CEOs 9:47 p.m. Nov. 19, 2013 - WSJ.com
QIAGEN, Eli Lilly Expand Partnership - Analyst Blog 6:58 p.m. Nov. 19, 2013 - Zacks.com
Press Releases on PFE
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV 9:00 a.m. Nov. 22, 2013 - PR Newswire
Pfizer's XALKORI(R) Granted Regular FDA Approval 11:00 a.m. Nov. 21, 2013 - BusinessWire
Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma 8:00 a.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer 7:00 a.m. Nov. 21, 2013 - GlobeNewswire
Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align Technology 8:00 a.m. Nov. 19, 2013 - PR Newswire
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ(R) (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis 4:47 p.m. Nov. 18, 2013 - BusinessWire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014 8:30 a.m. Nov. 14, 2013 - BusinessWire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Athersys Recognized Among Fastest Growing Companies in North America on Deloitte's 2013 Technology Fast 500(TM) 2:00 p.m. Nov. 13, 2013 - GlobeNewswire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients 8:00 a.m. Nov. 8, 2013 - BusinessWire
The Global Revolution in Biotechnology and the Impact of Regenerative Medicine 9:53 a.m. Nov. 7, 2013 - ACCESSWIRE
GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting 9:11 a.m. Nov. 7, 2013 - BusinessWire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
2013 mHealth Summit Launches First Pharma and Life Sciences Roundtable 2:31 p.m. Nov. 6, 2013 - PR Newswire
Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern 12:32 p.m. Nov. 5, 2013 - BusinessWire
Pfizer Receives FDA Approval for a Prior Approval Supplement for EMBEDA(R) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII 5:14 p.m. Nov. 4, 2013 - BusinessWire
Therapeutic Area Partnerships Feature Pharma Leaders Who Unveil How to Pick Drug Targets, Partners, and Deal Models Most Likely to Succeed 9:00 a.m. Nov. 4, 2013 - Marketwire
Valuation
P/E Current
24.64
P/E Ratio (with extraordinary items)
5.91
P/E Ratio (without extraordinary items)
19.24
Price to Sales Ratio
3.16
Price to Book Ratio
2.25
Price to Cash Flow Ratio
11.04
Enterprise Value to EBITDA
8.03
Enterprise Value to Sales
3.94
Total Debt to Enterprise Value
0.19
Efficiency
Revenue/Employee
0.64
Income Per Employee
0.10
Receivables Turnover
4.53
Total Asset Turnover
0.32
Liquidity
Current Ratio
2.15
Quick Ratio
1.90
Cash Ratio
1.14
Profitability
Gross Margin
72.52
Operating Margin
32.15
Pretax Margin
20.48
Net Margin
16.09
Return on Assets
5.08
Return on Equity
11.61
Return on Total Capital
7.91
Return on Invested Capital
8.27
Capital Structure
Total Debt to Total Equity
46.12
Total Debt to Total Capital
31.55
Total Debt to Total Assets
20.16
Long-Term Debt to Equity
38.21
Long-Term Debt to Total Capital
26.14
Pfizer Inc. PFE Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 48.3B 50.01B 67.06B 65.26B 58.99B
Cost of Goods Sold (COGS) incl. D&A 10.04B 11.59B 20.71B 18.82B 16.21B
COGS excluding D&A 4.95B 6.83B 12.23B 9.91B 8.6B
Depreciation & Amortization Expense 5.09B 4.76B 8.49B 8.91B 7.61B
Depreciation 2.29B 1.76B 3.08B 3.36B 2.44B
Amortization of Intangibles 2.8B 3B 5.4B 5.54B 5.18B
Gross Income 38.26B 38.42B 46.34B 46.44B 42.78B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 21.64B 22.41B 28.61B 27.13B 23.81B
Research & Development 7.51B 7.75B 9.36B 8.4B 7.34B
Other SG&A 14.12B 14.66B 19.25B 18.73B 16.47B
Other Operating Expense 0 0 0 0 0
Unusual Expense 8.36B 5.96B 8.03B 6.23B 6.13B
EBIT after Unusual Expense (8.36B) (5.96B) (8.03B) (6.23B) (6.13B)
Non Operating Income/Expense 653M 787M 971M 445M 382M
Non-Operating Interest Income 1.29B 746M 402M 456M 383M
Equity in Affiliates (Pretax) 0 482M 0 0 0
Interest Expense 516M 1.23B 1.8B 1.68B 1.52B
Gross Interest Expense 562M 1.27B 1.83B 1.73B 1.57B
Interest Capitalized 46M 34M 36M 50M 41M
Pretax Income 9.69B 10.83B 9.28B 12.3B 12.08B
Income Tax 1.65B 2.2B 1.07B 3.91B 2.56B
Income Tax - Current Domestic 861M 10.24B (3.08B) 1.56B (796M)
Income Tax - Current Foreign 2.12B 1.54B 2.21B 2.05B 2.62B
Income Tax - Deferred Domestic (30M) (10.1B) 2B 124M 523M
Income Tax - Deferred Foreign (1.3B) 513M (67M) 183M 216M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 8.05B 8.63B 8.21B 8.4B 9.52B
Minority Interest Expense 23M 9M 31M 40M 28M
Net Income 8.03B 8.62B 8.18B 8.36B 9.49B
Extraordinaries & Discontinued Operations 78M 14M 77M 1.65B 5.08B
Extra Items & Gain/Loss Sale Of Assets 80M 0 (11M) 1.3B 4.78B
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (2M) 14M 88M 350M 297M
Net Income After Extraordinaries 8.1B 8.64B 8.26B 10.01B 14.57B
Preferred Dividends 3M 2M 2M 2M 2M
Net Income Available to Common 8.02B 8.62B 8.18B 8.35B 9.49B
EPS (Basic) 1.19 1.23 1.03 1.11 1.32
Basic Shares Outstanding 6.73B 7.01B 8.04B 7.82B 7.44B
EPS (Diluted) 1.19 1.23 1.02 1.11 1.30
Diluted Shares Outstanding 6.75B 7.05B 8.07B 7.87B 7.51B
EBITDA 21.72B 20.77B 26.22B 28.22B 26.58B
Pfizer Inc. PFE Filings
SEC Filings for Pfizer Inc.
Filing Date Document Date Type Category Amended
11/08/2013 09/29/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
09/30/2013 09/27/2013 8-K Special Events
09/27/2013 N/A SC 13G Institutional Ownership
08/09/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
06/03/2013 05/28/2013 8-K Special Events
05/29/2013 05/22/2013 8-K Special Events
05/10/2013 03/31/2013 10-Q Quarterly Reports
04/30/2013 04/30/2013 8-K Special Events
04/29/2013 04/25/2013 8-K Special Events
03/14/2013 04/25/2013 DEF 14A Proxy Statement
03/01/2013 12/31/2012 10-K/A Annual Reports *
02/28/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
01/29/2013 01/29/2013 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
11/01/2012 11/01/2012 8-K Special Events
08/14/2012 08/13/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
PFE Pfizer Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
Pfizer, Inc. is a research-based, global biopharmaceutical company. The company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products. It also collaborates with other biopharmaceutical companies, healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. It operates through five operating segments: Primary Care, Specialty Care and Oncology, Established Products & Emerging Markets, Animal Health, and Consumer Healthcare. The Primary Care segment includes products in therapeutic and disease areas: Alzheimer's disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory and smoking cessation. The Specialty Care and Oncology segment comprises the Specialty Care business unit and the Oncology business unit. The Specialty Care business unit includes products in the following therapeutic and disease areas: anti-infectives, endocrine disorders, hemophilia, inflammation, multiple sclerosis, ophthalmology, pulmonary arterial hypertension, specialty neuroscience and vaccines. The Oncology business unit includes pharmaceutical products addressing oncology and oncology-related illnesses. The Established Products & Emerging Markets segment comprises the Established Products business unit and the Emerging Markets business unit. The Established Products unit includes pharmaceutical products that have lost patent protection or marketing exclusivity in certain countries and/or regions. The Emerging Markets unit includes human prescription pharmaceutical products sold in emerging markets, including Asia, Latin America, Middle East, Africa, Central and Eastern Europe and Turkey. The Animal Health & Consumer Healthcare segment comprises the Animal Health business unit and the Consumer Healthcare business unit. The Animal Health unit includes products and services to prevent and treat disease in livestock and companion animals, including vaccines, parasiticides and anti-infectives. The Consumer Healthcare segment includes non-prescription products in the following therapeutic categories: dietary supplements, pain management, respiratory and personal care. The company was founded by Charles Pfizer and Charles Erhart in 1849 and is headquartered in New York, NY.
PFE Last Price: 32.09
Last Updated: November 24, 2013 1:23 AM EST
PFE Stock Message Board and Forum http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Pfizer Inc. PFE Officers and Executives
Name Age Officer Since Title
Mr. Ian C. Read 59 - Chairman & Chief Executive Officer
Dr. Olivier Brandicourt 57 2007 President & General Manager-Emerging Markets
Mr. Frank A. D'Amelio 55 2007 Chief Financial Officer & EVP-Business Operations
Dr. Mikael Dolsten 54 2009 President-Worldwide Research & Development
Mr. Steve Felstead - - Vice President & Head-Clinical Research
Pfizer Inc.
235 East 42nd Street
New York, New York 10017-5755
Phone
1 2127332323
Industry
Pharmaceuticals
Sector
Health Care
Fiscal Year-end
12/2013
View SEC Filings Below
Revenue
$58.99B
Net Income
$9.49B
Employees
91,500
Annual Report Below for PFE
Pfizer Inc. PFE Recent Headlines
MarketWatch News on PFE
Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Pfizer profit falls, adjusts full-year views 7:24 a.m. Oct. 29, 2013 - MarketWatch.com
Pfizer net falls, adjusts full-year earnings range 7:18 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 revenue down 2% to $12.64 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 profit falls 19% to $2.59 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 EPS falls to $0.39; adj. EPS up to $0.58 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Cat's warning sign, a Michael Kors pop and the surf pounds Portugal 6:11 a.m. Oct. 29, 2013 - blogs.marketwatch.com
Apple, LinkedIn, Pfizer, Michael Kors: hot stocks 5:30 a.m. Oct. 29, 2013 - Ben Eisen
Pfizer Feels the Heat From Novartis 4:14 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Neurotrope: Intriguing Play On Alzheimer's 3:58 p.m. Nov. 22, 2013 - Seeking Alpha
Novartis ambushes Pfizer with breast cancer treatment 3:06 p.m. Nov. 22, 2013 - Seeking Alpha
4 Biotech Stocks Making Big Moves 12:47 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Two Small-Cap Biotechs to Watch 12:00 p.m. Nov. 22, 2013 - RealMoney.com
Wall Street Breakfast: Must-Know News 6:33 a.m. Nov. 22, 2013 - Seeking Alpha
Novartis to repurchase $5B in shares over two years 4:24 a.m. Nov. 22, 2013 - Seeking Alpha
Pfizer Gets FDA Nod for Xalkori Lung Cancer Drug and 2 Other Dow Movers to Watch 1:53 p.m. Nov. 21, 2013 - Wall St. Cheat Sheet
Data on Amgen's Pipeline Candidates - Analyst Blog 11:50 a.m. Nov. 21, 2013 - Zacks.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com
Athersys Narrows Loss, Shares Rise - Analyst Blog 9:00 a.m. Nov. 21, 2013 - Zacks.com
Daiichi Sankyo's Factor Xa Inhibitor Edoxaban Clears Phase III Hurdle - A Major Threat To Xarelto And Eliquis 8:35 a.m. Nov. 21, 2013 - Seeking Alpha
Roche's Kadcyla Approved in the EU - Analyst Blog 5:35 p.m. Nov. 20, 2013 - Zacks.com
Will Recent News Hurt Johnson & Johnson? 5:08 p.m. Nov. 20, 2013 - Wall St. Cheat Sheet
Amazon.com Cloud Push Seen Creating 'Losers' In IT 4:21 p.m. Nov. 20, 2013 - Investors Business Daily
Early Warning Signs of a Dividend Cut 10:39 a.m. Nov. 20, 2013 - GuruFocus.com
Daiichi Sankyo's edoxaban holds its own in clinical testing 10:26 a.m. Nov. 20, 2013 - Seeking Alpha
EU Clears Roche Cancer Drug 5:44 a.m. Nov. 20, 2013 - WSJ.com
More Boards Recruit Ex-CEOs 9:47 p.m. Nov. 19, 2013 - WSJ.com
QIAGEN, Eli Lilly Expand Partnership - Analyst Blog 6:58 p.m. Nov. 19, 2013 - Zacks.com
Press Releases on PFE
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV 9:00 a.m. Nov. 22, 2013 - PR Newswire
Pfizer's XALKORI(R) Granted Regular FDA Approval 11:00 a.m. Nov. 21, 2013 - BusinessWire
Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma 8:00 a.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer 7:00 a.m. Nov. 21, 2013 - GlobeNewswire
Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align Technology 8:00 a.m. Nov. 19, 2013 - PR Newswire
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ(R) (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis 4:47 p.m. Nov. 18, 2013 - BusinessWire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014 8:30 a.m. Nov. 14, 2013 - BusinessWire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Athersys Recognized Among Fastest Growing Companies in North America on Deloitte's 2013 Technology Fast 500(TM) 2:00 p.m. Nov. 13, 2013 - GlobeNewswire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients 8:00 a.m. Nov. 8, 2013 - BusinessWire
The Global Revolution in Biotechnology and the Impact of Regenerative Medicine 9:53 a.m. Nov. 7, 2013 - ACCESSWIRE
GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting 9:11 a.m. Nov. 7, 2013 - BusinessWire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
2013 mHealth Summit Launches First Pharma and Life Sciences Roundtable 2:31 p.m. Nov. 6, 2013 - PR Newswire
Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern 12:32 p.m. Nov. 5, 2013 - BusinessWire
Pfizer Receives FDA Approval for a Prior Approval Supplement for EMBEDA(R) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII 5:14 p.m. Nov. 4, 2013 - BusinessWire
Therapeutic Area Partnerships Feature Pharma Leaders Who Unveil How to Pick Drug Targets, Partners, and Deal Models Most Likely to Succeed 9:00 a.m. Nov. 4, 2013 - Marketwire
Valuation
P/E Current
24.64
P/E Ratio (with extraordinary items)
5.91
P/E Ratio (without extraordinary items)
19.24
Price to Sales Ratio
3.16
Price to Book Ratio
2.25
Price to Cash Flow Ratio
11.04
Enterprise Value to EBITDA
8.03
Enterprise Value to Sales
3.94
Total Debt to Enterprise Value
0.19
Efficiency
Revenue/Employee
0.64
Income Per Employee
0.10
Receivables Turnover
4.53
Total Asset Turnover
0.32
Liquidity
Current Ratio
2.15
Quick Ratio
1.90
Cash Ratio
1.14
Profitability
Gross Margin
72.52
Operating Margin
32.15
Pretax Margin
20.48
Net Margin
16.09
Return on Assets
5.08
Return on Equity
11.61
Return on Total Capital
7.91
Return on Invested Capital
8.27
Capital Structure
Total Debt to Total Equity
46.12
Total Debt to Total Capital
31.55
Total Debt to Total Assets
20.16
Long-Term Debt to Equity
38.21
Long-Term Debt to Total Capital
26.14
Pfizer Inc. PFE Financials
Fiscal year is January-December. All values USD millions. 2008 2009 2010 2011 2012 5-year trend
Sales/Revenue 48.3B 50.01B 67.06B 65.26B 58.99B
Cost of Goods Sold (COGS) incl. D&A 10.04B 11.59B 20.71B 18.82B 16.21B
COGS excluding D&A 4.95B 6.83B 12.23B 9.91B 8.6B
Depreciation & Amortization Expense 5.09B 4.76B 8.49B 8.91B 7.61B
Depreciation 2.29B 1.76B 3.08B 3.36B 2.44B
Amortization of Intangibles 2.8B 3B 5.4B 5.54B 5.18B
Gross Income 38.26B 38.42B 46.34B 46.44B 42.78B
2008 2009 2010 2011 2012 5-year trend
SG&A Expense 21.64B 22.41B 28.61B 27.13B 23.81B
Research & Development 7.51B 7.75B 9.36B 8.4B 7.34B
Other SG&A 14.12B 14.66B 19.25B 18.73B 16.47B
Other Operating Expense 0 0 0 0 0
Unusual Expense 8.36B 5.96B 8.03B 6.23B 6.13B
EBIT after Unusual Expense (8.36B) (5.96B) (8.03B) (6.23B) (6.13B)
Non Operating Income/Expense 653M 787M 971M 445M 382M
Non-Operating Interest Income 1.29B 746M 402M 456M 383M
Equity in Affiliates (Pretax) 0 482M 0 0 0
Interest Expense 516M 1.23B 1.8B 1.68B 1.52B
Gross Interest Expense 562M 1.27B 1.83B 1.73B 1.57B
Interest Capitalized 46M 34M 36M 50M 41M
Pretax Income 9.69B 10.83B 9.28B 12.3B 12.08B
Income Tax 1.65B 2.2B 1.07B 3.91B 2.56B
Income Tax - Current Domestic 861M 10.24B (3.08B) 1.56B (796M)
Income Tax - Current Foreign 2.12B 1.54B 2.21B 2.05B 2.62B
Income Tax - Deferred Domestic (30M) (10.1B) 2B 124M 523M
Income Tax - Deferred Foreign (1.3B) 513M (67M) 183M 216M
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 8.05B 8.63B 8.21B 8.4B 9.52B
Minority Interest Expense 23M 9M 31M 40M 28M
Net Income 8.03B 8.62B 8.18B 8.36B 9.49B
Extraordinaries & Discontinued Operations 78M 14M 77M 1.65B 5.08B
Extra Items & Gain/Loss Sale Of Assets 80M 0 (11M) 1.3B 4.78B
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (2M) 14M 88M 350M 297M
Net Income After Extraordinaries 8.1B 8.64B 8.26B 10.01B 14.57B
Preferred Dividends 3M 2M 2M 2M 2M
Net Income Available to Common 8.02B 8.62B 8.18B 8.35B 9.49B
EPS (Basic) 1.19 1.23 1.03 1.11 1.32
Basic Shares Outstanding 6.73B 7.01B 8.04B 7.82B 7.44B
EPS (Diluted) 1.19 1.23 1.02 1.11 1.30
Diluted Shares Outstanding 6.75B 7.05B 8.07B 7.87B 7.51B
EBITDA 21.72B 20.77B 26.22B 28.22B 26.58B
Pfizer Inc. PFE Filings
SEC Filings for Pfizer Inc.
Filing Date Document Date Type Category Amended
11/08/2013 09/29/2013 10-Q Quarterly Reports
10/29/2013 10/29/2013 8-K Special Events
09/30/2013 09/27/2013 8-K Special Events
09/27/2013 N/A SC 13G Institutional Ownership
08/09/2013 06/30/2013 10-Q Quarterly Reports
07/30/2013 07/30/2013 8-K Special Events
06/03/2013 05/28/2013 8-K Special Events
05/29/2013 05/22/2013 8-K Special Events
05/10/2013 03/31/2013 10-Q Quarterly Reports
04/30/2013 04/30/2013 8-K Special Events
04/29/2013 04/25/2013 8-K Special Events
03/14/2013 04/25/2013 DEF 14A Proxy Statement
03/01/2013 12/31/2012 10-K/A Annual Reports *
02/28/2013 12/31/2012 10-K Annual Reports
02/14/2013 N/A SC 13G/A Institutional Ownership *
02/05/2013 N/A SC 13G/A Institutional Ownership *
01/29/2013 01/29/2013 8-K Special Events
11/09/2012 09/30/2012 10-Q Quarterly Reports
11/01/2012 11/01/2012 8-K Special Events
08/14/2012 08/13/2012 8-K Special Events
SEC Filings provided by EDGAR Online, Inc.
PFE Pfizer Inc. Research Links
Stock Message Board http://investorshangout.com/search?q=PFE&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/PFE/quote
Stock Chart http://www.otcmarkets.com/stock/PFE/chart
Company Info http://www.otcmarkets.com/stock/PFE/company-info
Recent News http://www.otcmarkets.com/stock/PFE/news
Financials http://www.otcmarkets.com/stock/PFE/financials
Filings and Disclosure http://www.otcmarkets.com/stock/PFE/filings
Short Sales http://www.otcmarkets.com/stock/PFE/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/PFE/insider-transactions
Research Reports http://www.otcmarkets.com/stock/PFE/research
Summary http://finance.yahoo.com/q?s=PFE
Historical Prices http://finance.yahoo.com/q/hp?s=PFE+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=PFE
Basic Chart http://finance.yahoo.com/q/bc?s=PFE+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=PFE+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=PFE+Headlines
Press Releases http://finance.yahoo.com/q/p?s=PFE+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=PFE+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=PFE+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=PFE+Industry
Major Holders http://finance.yahoo.com/q/mh?s=PFE+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=PFE+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=PFE+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=PFE
Balance Sheet http://finance.yahoo.com/q/bs?s=PFE
Cash Flow http://finance.yahoo.com/q/cf?s=PFE+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/PFE
Market Watch http://www.marketwatch.com/investing/stock/PFE
Bloomberg http://www.bloomberg.com/quote/PFE:US
Morningstar http://quotes.morningstar.com/stock/s?t=PFE
Bussinessweek http://investing.businessweek.com/research/st...ticker=PFE
Barchart http://www.barchart.com/quotes/stocks/PFE
OTC Short Report http://otcshortreport.com/index.php?index=PFE
Investopedia http://www.investopedia.com/markets/stocks/PFE/?wa=0
List of all stock message boards and tickers for NYSE New York Stock Exchange http://investorshangout.com/board?categoryid=NYSE
